niacinamide has been researched along with Cancer of the Uterus in 2 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the efficacy and safety of single agent sorafenib, an oral multi-targeted tyrosine kinase inhibitor, in patients with advanced uterine carcinoma and carcinosarcoma." | 9.14 | A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. ( Agamah, E; Elit, L; Fleming, GF; Huo, D; Knost, JA; Morgan, RJ; Nimeiri, HS; Oza, AM; Vokes, EE; Wade, JL, 2010) |
| "To determine the efficacy and safety of single agent sorafenib, an oral multi-targeted tyrosine kinase inhibitor, in patients with advanced uterine carcinoma and carcinosarcoma." | 5.14 | A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. ( Agamah, E; Elit, L; Fleming, GF; Huo, D; Knost, JA; Morgan, RJ; Nimeiri, HS; Oza, AM; Vokes, EE; Wade, JL, 2010) |
| "Perivascular epithelioid cell tumor is a rare tumor." | 1.43 | Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa. ( Gao, F; Huang, C; Sun, R; Wang, H; Zhang, S; Zhang, Y, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, F | 1 |
| Huang, C | 1 |
| Zhang, Y | 2 |
| Sun, R | 1 |
| Wang, H | 1 |
| Zhang, S | 1 |
| Nimeiri, HS | 1 |
| Oza, AM | 1 |
| Morgan, RJ | 1 |
| Huo, D | 1 |
| Elit, L | 1 |
| Knost, JA | 1 |
| Wade, JL | 1 |
| Agamah, E | 1 |
| Vokes, EE | 1 |
| Fleming, GF | 1 |
1 trial available for niacinamide and Cancer of the Uterus
| Article | Year |
|---|---|
A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma; Carcinosarcoma; | 2010 |
1 other study available for niacinamide and Cancer of the Uterus
| Article | Year |
|---|---|
Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa.
Topics: Antineoplastic Agents; Female; Humans; Middle Aged; Niacinamide; Perivascular Epithelioid Cell Neopl | 2016 |